US Stock MarketDetailed Quotes
SPRO Spero Therapeutics
- 1.460
- +0.030+2.10%
Close Apr 26 16:00 ET
- 1.450
- -0.010-0.68%
Post 16:16 ET
78.68MMarket Cap3.40P/E (TTM)
1.510High1.420Low165.36KVolume1.440Open1.430Pre Close241.46KTurnover0.42%Turnover Ratio3.40P/E (Static)53.89MShares1.99552wk High0.74P/B58.13MFloat Cap0.99052wk Low--Dividend TTM39.82MShs Float23.639Historical High--Div YieldTTM6.29%Amplitude0.680Historical Low1.460Avg Price1Lot Size
Spero Therapeutics Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | (Q2)Jun 30, 2022 | (Q1)Mar 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -326.79%-33M | -139.33%-17.49M | 1,763.01%15.92M | 19.40%-18.56M | 54.46%-12.85M | 87.99%-7.73M | 262.65%44.48M | 80.67%-957K | -39.03%-23.03M | -82.33%-28.22M |
| Net income from continuing operations | 149.13%22.81M | 91.22%51.19M | 72.55%-3.21M | 58.46%-11.91M | 59.59%-13.27M | 48.29%-46.42M | 191.56%26.77M | 48.16%-11.68M | -54.44%-28.68M | -69.02%-32.83M |
| Operating gains losses | ---- | ---- | ---- | ---- | ---- | 1,500.00%2.67M | 33.17%-139K | 285.71%27K | 8,879.31%2.6M | 1,057.89%182K |
| Depreciation and amortization | -57.77%367K | -70.54%38K | -57.98%108K | -63.27%108K | -40.21%113K | 34.52%869K | -32.46%129K | 73.65%257K | 98.65%294K | 18.87%189K |
| Other non cash items | -70.48%969K | 7.33%249K | 7.02%244K | 110.53%240K | -91.29%236K | 36.17%3.28M | -87.11%232K | 0.00%228K | -40.93%114K | 1,325.79%2.71M |
| Change In working capital | -418.63%-70.38M | -573.37%-70.97M | 54.78%11.55M | -765.79%-8.86M | -23.88%-2.11M | 71.72%22.09M | 621.64%14.99M | -49.50%7.47M | 326.19%1.33M | -210.32%-1.7M |
| -Change in receivables | -129.80%-461K | 1,202.29%1.44M | -244.39%-901K | -156.74%-223K | -218.15%-781K | -59.63%1.55M | -147.17%-131K | 258.38%624K | -94.16%393K | 127.02%661K |
| -Change in prepaid assets | -115.24%-799K | 165.04%1.23M | -9.29%3.16M | -239.09%-5.03M | -629.03%-164K | 286.68%5.24M | 66.03%-1.89M | 132.47%3.49M | 829.31%3.62M | -96.43%31K |
| -Change in payables and accrued expense | 78.37%-1.27M | 160.35%656K | 66.67%755K | 29.92%-2.53M | 91.00%-145K | -385.07%-5.86M | -133.61%-1.09M | -72.68%453K | 41.19%-3.62M | -148.63%-1.61M |
| -Change in other current assets | -3,191,333.33%-95.74M | -9,574,200.00%-95.74M | --0 | --0 | --0 | 99.06%-3K | 99.69%-1K | -90,600.00%-907K | 14,775.00%1.19M | ---285K |
| -Change in other current liabilities | -52.47%-1.11M | 1.13%-262K | -164.55%-291K | -170.48%-284K | -10.40%-276K | -34.69%-730K | -388.04%-265K | 52.99%-110K | 48.78%-105K | -28.21%-250K |
| -Change in other working capital | 32.51%29.01M | 18.18%21.71M | 125.32%8.83M | -434.69%-786K | -200.81%-740K | 105.69%21.89M | 7,302.75%18.37M | -68.03%3.92M | ---147K | ---246K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -326.79%-33M | -139.33%-17.49M | 1,763.01%15.92M | 19.40%-18.56M | 54.46%-12.85M | 87.99%-7.73M | 262.65%44.48M | 80.67%-957K | -39.03%-23.03M | -82.33%-28.22M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 0 | 0 | 0 | 0 | 0 | 340.65%33.81M | 0 | -100.76%-129K | 357.92%50M | -634.93%-16.06M |
| Net investment purchase and sale | --0 | --0 | --0 | --0 | --0 | 342.91%33.81M | --0 | --0 | 356.74%49.87M | -634.93%-16.06M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | --0 | --0 | --0 | --0 | --0 | 340.65%33.81M | --0 | -100.76%-129K | 357.92%50M | -634.93%-16.06M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 100.75%221K | -99.99%1K | -96.41%220K | 0 | 0 | -135.16%-29.55M | -71.84%14.18M | -79.02%6.13M | -32,050.60%-53.68M | -11.49%3.81M |
| Net common stock issuance | -99.10%221K | -99.99%1K | -96.41%220K | --0 | --0 | -30.69%24.51M | 473.08%14.18M | -78.59%6.13M | --577K | -14.74%3.63M |
| Proceeds from stock option exercised by employees | --0 | --0 | --0 | --0 | --0 | -71.03%420K | -99.57%1K | --0 | -16.61%231K | 102.15%188K |
| Net other financing activities | ---- | ---- | ---- | ---- | ---- | -215.36%-54.49M | --0 | --0 | ---- | ---- |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 100.75%221K | -99.99%1K | -96.41%220K | --0 | --0 | -135.16%-29.55M | -71.84%14.18M | -79.02%6.13M | -32,050.60%-53.68M | -11.49%3.81M |
| Net cash flow | ||||||||||
| Beginning cash position | -3.09%109.11M | 85.99%93.83M | 71.12%77.69M | 33.48%96.25M | -3.09%109.11M | 32.13%112.58M | -55.30%50.45M | -36.56%45.4M | -6.40%72.11M | 32.13%112.58M |
| Current changes in cash | -842.59%-32.77M | -129.82%-17.49M | 219.82%16.14M | 30.50%-18.56M | 68.24%-12.85M | -112.70%-3.48M | 21,431.27%58.66M | -87.78%5.05M | -387.41%-26.71M | -395.57%-40.47M |
| End cash Position | -30.04%76.33M | -30.04%76.33M | 85.99%93.83M | 71.12%77.69M | 33.48%96.25M | -3.09%109.11M | -3.09%109.11M | -55.30%50.45M | -36.56%45.4M | -6.40%72.11M |
| Free cash flow | -326.79%-33M | -139.33%-17.49M | 1,763.01%15.92M | 19.40%-18.56M | 54.46%-12.85M | 87.99%-7.73M | 262.65%44.48M | 80.67%-957K | -39.03%-23.03M | -82.33%-28.22M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg